NCT01666743View on ClinicalTrials.gov

Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

March 31, 2014

Conditions
Community-Acquired Bacterial Pneumonia (CABP)
Interventions
DRUG

Ceftaroline fosamil

IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)

Sponsors
All Listed Sponsors
lead

Forest Laboratories

INDUSTRY

NCT01666743 - Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia | Biotech Hunter | Biotech Hunter